A detailed history of Shell Asset Management CO transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 883 shares of VKTX stock, worth $35,143. This represents 0.0% of its overall portfolio holdings.

Number of Shares
883
Previous 2,458 64.08%
Holding current value
$35,143
Previous $65,000 64.62%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025

SELL
$23.09 - $42.09 $36,366 - $66,291
-1,575 Reduced 64.08%
883 $23,000
Q2 2025

Jul 23, 2025

SELL
$19.98 - $29.49 $5,394 - $7,962
-270 Reduced 9.9%
2,458 $65,000
Q1 2025

May 14, 2025

SELL
$24.15 - $42.89 $2,849 - $5,061
-118 Reduced 4.15%
2,728 $66,000
Q3 2024

Nov 07, 2024

SELL
$49.84 - $70.47 $8,123 - $11,486
-163 Reduced 5.42%
2,846 $180,000
Q1 2024

Jul 31, 2024

SELL
$17.4 - $94.5 $3,288 - $17,860
-189 Reduced 5.91%
3,009 $160,000
Q1 2024

May 14, 2024

BUY
$17.4 - $94.5 $55,645 - $302,211
3,198 New
3,198 $262,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.